Olafertinib

N/A

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameOlafertinib
Drug Alias NameCovalent 3rd generation EGFR inhibitors - Fortress Biotech/NeuPharmaIrreversible third generation EGFR inhibitors - Fortress Biotech/NeuPharmaCK-101RX-518CS-2481 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR L858R inhibitorsEGFR T790M inhibitorsEGFR 19del inhibitors +[4] 
TargetsEpidermal growth factor receptor erbB1EGFR L858REGFR T790M +[4] 
Therapy Area/IndicationsLung DiseasesCarcinoma, Non-Small-Cell LungLung Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandThailand +[6] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSuzhou Neupharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSuzhou Neupharma Co LtdCheckpoint Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLung DiseasesCarcinoma, Non-Small-Cell LungLung Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A